NASDAQ
Akero Therapeutics, Inc. (AKRO) has a consensus Buy rating from 14 analysts with an average price target of $48.40, representing -11.4% downside from the current price of $54.65.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Oct 10, 2025 | Unknown | H.C. Wainwright | $54.00 | $54.08 | -0.15% |
| Oct 9, 2025 | Unknown | Jefferies | $56.00 | $54.15 | +3.42% |
| Oct 9, 2025 | Unknown | Canaccord Genuity | $54.00 | $54.19 | -0.34% |
| Sep 4, 2025 | Andrew Fein | H.C. Wainwright | $72.00 | $45.62 |
Oct 10, 2025 | Downgrade | Wolfe Research | Outperform | Peer Perform |
Oct 10, 2025 | Downgrade | HC Wainwright & Co. | Buy | Neutral |
Oct 9, 2025 | Downgrade | Jefferies | Buy | Hold |
Oct 9, 2025 | Downgrade | Canaccord Genuity | Buy | Hold |
May 27, 2025 | Maintained | B of A Securities | Buy | Buy |
| Sep 17, 2024 | Ed Arce | H.C. Wainwright | $50.00 | $26.97 | +85.39% |
No price data available for this timeframe.